Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has scheduled its first quarter 2025 financial results announcement and corporate update for May 13, 2025, at 8:30 AM ET. The company will host a conference call accessible via toll-free number 1-800-717-1738 (Conference ID: 53983) and webcast. A replay of the presentation will be made available in the Events section of the company's Investor Relations website.
Cellectar Biosciences (NASDAQ: CLRB), un'azienda biofarmaceutica in fase avanzata specializzata nello sviluppo di farmaci per il trattamento del cancro, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 e un aggiornamento aziendale per il 13 maggio 2025 alle 8:30 ET. La società terrà una teleconferenza accessibile tramite il numero verde 1-800-717-1738 (ID conferenza: 53983) e webcast. Una replica della presentazione sarà disponibile nella sezione Eventi del sito web per gli Investitori della società.
Cellectar Biosciences (NASDAQ: CLRB), una empresa biofarmacéutica en etapa avanzada especializada en el desarrollo de medicamentos para el tratamiento del cáncer, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 y una actualización corporativa para el 13 de mayo de 2025 a las 8:30 AM ET. La compañía realizará una llamada telefónica accesible a través del número gratuito 1-800-717-1738 (ID de conferencia: 53983) y webcast. Una repetición de la presentación estará disponible en la sección de Eventos del sitio web de Relaciones con Inversionistas de la empresa.
Cellectar Biosciences (NASDAQ: CLRB)는 암 치료제 개발을 전문으로 하는 후기 임상 단계 바이오제약 회사로, 2025년 5월 13일 오전 8시 30분(동부시간)에 2025년 1분기 재무 결과 발표 및 기업 업데이트를 예정하고 있습니다. 회사는 무료 전화번호 1-800-717-1738(회의 ID: 53983) 및 웹캐스트를 통해 컨퍼런스 콜을 진행할 예정입니다. 발표 녹화는 회사 투자자 관계 웹사이트의 이벤트 섹션에서 제공될 예정입니다.
Cellectar Biosciences (NASDAQ: CLRB), une société biopharmaceutique en phase clinique avancée spécialisée dans le développement de médicaments contre le cancer, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 et une mise à jour d'entreprise pour le 13 mai 2025 à 8h30 ET. La société organisera une conférence téléphonique accessible via le numéro vert 1-800-717-1738 (ID de conférence : 53983) ainsi qu'un webcast. Une rediffusion de la présentation sera disponible dans la section Événements du site Internet des Relations Investisseurs de la société.
Cellectar Biosciences (NASDAQ: CLRB), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Entwicklung von Krebsbehandlungsmitteln spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 und ein Unternehmensupdate für den 13. Mai 2025 um 8:30 Uhr ET geplant. Das Unternehmen wird eine Telefonkonferenz über die gebührenfreie Nummer 1-800-717-1738 (Konferenz-ID: 53983) und einen Webcast veranstalten. Eine Aufzeichnung der Präsentation wird im Bereich Veranstaltungen auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2025, and provide a corporate update on May 13, 2025, at 8:30 a.m. Eastern Time.
| Conference Call & Webcast Details: | |
| Date: | Tuesday, May 13, 2025 |
| Time: | 8:30 am Eastern Time |
| Toll Free: | 1-800-717-1738 |
| Conference ID: | 53983 |
| Webcast: | Click HERE |
A replay of the corporate presentation will be available on the Events section of the Company’s Investor Relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 125, an iodine-125 Auger-emitting program targeted in solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug, and two Fast Track designations for various cancer indications. The EMA (European Medicines Agency) has granted iopofosine I 131 two Orphan Drug designations and PRIME designation for WM.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook.
Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
FAQ
When will Cellectar Biosciences (CLRB) report Q1 2025 earnings?
How can I access Cellectar Biosciences' Q1 2025 earnings call?
What is Cellectar Biosciences' (CLRB) main business focus?
Where can I find the replay of Cellectar Biosciences' Q1 2025 earnings call?
